Avid Bioservices (CDMO) Reports Q3 Loss of $0.05/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2019 and Recent Developments
March 11, 2019 4:05 PM EDT-- Achieved Revenue of $13.8 Million, an Increase of 102%Compared to Prior Year Quarter --
-- Signed Project Expansion Orders with Existing Customers Representing $23.8 Million --
-- Completed Process Validation Campaign for Future Commercial Production with Other Validations Ongoing --
TUSTIN, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (NASDAQ: CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and... More
